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Objective. To compare ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI) for clinical
differential diagnosis in patients with salivary gland tumor (SGT).
Study Design. Six databases were used to search the literature published between 1982 and 2013. Histologic diagnosis was
required as standard diagnosis. Pooled estimate for sensitivity, specificity, summary receiver-operating characteristic curve
(SROC) and area under curve (AUC) were calculated and compared using STATA and Meta-Disc statistical software.
Results. Nineteen articles were included. Pooled sensitivity for US, CT, and MRI was 0.629 (95% confidence interval [CI]
0.52-0.73), 0.830 (95% CI 0.74-0.90), and 0.807 (95% CI 0.73-0.87), respectively; pooled specificity for US, CT, and MRI was
0.920 (95% CI 0.89-0.94), 0.851 (95% CI 0.79-0.90), and 0.886 (95% CI 0.85-0.92), respectively. The AUC under SROC for
US, CT, and MRI was 0.934  0.058, 0.912  0.889, and 0.903  0.045, respectively.
Conclusions. CT is recommended, as it is an effective imaging tool for differential diagnosis in patients with primary SGT, and
MRI is suggested for differential diagnosis between benign and malignant GSTs because of its highest sensitivity and
specificity. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:238-245)Salivary gland tumors (SGTs) account for about 3% of
head and neck tumors.1 SGTs are clinically asymp-
tomatic until they grow to a great volume or involve
adjacent structures, such as nerves, ducts, or muscles.
SGTs occur mostly in the parotid, submandibular, and
sublingual glands. When SGTs are located superﬁ-
cially, they are usually easy to ﬁnd; however, when the
tumor is deep or at an early stage, it might be difﬁcult to
identify. Some imaging examinations, such as ultraso-
nography (US), computed tomography (CT), and
magnetic resonance imaging (MRI), are necessary and
are helpful for clinical diagnosis.2 Although ﬁne-needle
aspiration biopsy (FNAB) is the most deﬁnitive tool to
determine whether the lesion is benign or malignant, it
is sometimes difﬁcult to perform due to unusual loca-
tion of the tumor or patients’ unwillingness to undergo
FNAB. In addition, FNAB is a more invasive procedure
that usually requires local anesthesia as well as CT or
US guidance.3 FNAB could also modify the tumor
structures and cause necrosis, hemorrhage, ﬁbrosis, and
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Open access under CC BY-NC-ND license.histologic evaluation more difﬁcult.4,5 The accuracy of
the evaluation depends on the quality of the sample
(quantity of tissue; avoidance of nonspeciﬁc areas, such
as cystic changes or necrosis) and the pathologist’s
experience.6 When FNAB is unavailable, imaging ex-
amination is helpful for establishing the clinical diag-
nosis and making the treatment plan.
The most common benign SGTs are pleomorphic
adenoma, adenolymphoma, basal cell adenoma,
oxyphilic adenoma, myoepithelioma, and papillary
cystadenoma.7 The most common malignant SGTs are
adenoid cystic carcinoma, mucoepidermoid carcinoma,
acinic cell carcinoma, and adenocarcinoma.8 The
common characteristics of benign SGTs delineated by
CT and MRI are sharp margins, round shape, and
uniform distribution of density; other characteristics of
benign SGTs seen on MRI include a low-density signal
with T1-weighted images and a high-density signal
with T2-weighted images. The common characteristics
of malignant SGTs seen on CT and MRI are irregularity
and intraglandular extension.9,10 Gadolinium-enhanced
dynamic MRI and diffusion-weighted echo-planar
imaging MRI with apparent diffusion coefﬁcientStatement of Clinical Relevance
Imaging examinations are very helpful for clinical
diagnosis when ﬁne-needle aspiration biopsy is
difﬁcult to perform due to unusual tumor location or
patients’ unwillingness. Ultrasonography (US),
computed tomography (CT), and magnetic reso-
nance imaging (MRI) are reliable methods for
diagnosing salivary gland tumors (SGTs) clinically.
Fig. 1. Flowchart of articles included in this meta-analysis.
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in distinguishing between benign and malignant parotid
gland tumors.11 The common US characteristics of
parotid masses include shape, margin, echogenicity,
echotexture, and vascularization. Some studies focus on
the different criteria of these US characteristics for
differential diagnosis of parotid tumors; for example, B-
mode sonography and elastographic sonography have
been investigated on the basis of these characteristics to
differentiate between benign and malignant parotid tu-
mors.12 However, it is sometimes difﬁcult to differen-
tiate malignant SGTs from benign SGTs.
In this meta-analysis, we assessed the diagnostic
capability of US, CT, and MRI and compared these
ﬁndings with the standard pathologic results, with the
aim of identifying the best imaging modality for diag-
nostic accuracy in SGT.METHODS
Literature search
Five databases, including Embase, Pubmed, Spring-
erlink, Sciencedirect, and Cochrane library databases,
were searched for publications from September 1982
to April 2013. The data used were limited to those
ofﬁcially published in English. Key words included
“salivary gland,” “parotid gland,” “submandibular
gland,” “sublingual gland,” “salivary ducts,” or “von
Ebner glands”; “US,” “ultrasound,” “ultrasonogra-
phy,” “ultrasonic diagnosis,” “CT,” “computed to-
mography,” “computerized tomography,” “MR,”
“MRI,” or “magnetic resonance imaging”; and
“sensitivity,” “speciﬁcity,” or “accuracy”. The article
search steps are shown in Figure 1. All articles were
required to have lesion origin, pathologic diagnosis,
study type, and one of US, CT, or MRI results. True
positive (TP), false positive (FP), true negative (TN),
and false negative (FN) diagnostic results indifferentiating malignant and benign tumor were also
required to be reported in the articles. This study was
exempt from approval by the ethics committee of the
Ninth People’s Hospital, Shanghai Jiao Tong Uni-
versity School of Medicine.Inclusion and exclusion criteria
The inclusion criteria were histologic diagnosis as ﬁnal
diagnosis, detailed description of each image exami-
nation, and speciﬁc regulation in differentiating malig-
nant SGTs from benign SGTs. The exclusion criteria
were study type being a review, case report, commen-
tary, editorial, or outcome without raw data.Data extraction
All data were extracted by two authors independently,
and any lack of clarity or disagreement was resolved
through discussion. The following items were deemed
essential: description of population, such as age and
gender ratios, publication year, study type, lesion number
and location, study design, and imaging analysis related
to our research. FP, TP, FN, and TN ratios were also
recorded. A standard form was designed and followed to
select potentially qualiﬁed articles. During data extrac-
tion, the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) tool was used as a guide line.13 The
QUADAS tool included 10 items to assess for risk of
bias, source of variation, and reporting quality. The
answer to each itemwas “yes,” “no,” or “unclear.”When
the answerwas “yes,” the item scored one point;when the
answer was “no,” the item scored minus one point; when
the answer was “unclear,” the item scored zero. The
QUADAS chart is shown in Supplementary Figure S1.
When the ﬁnal score was higher than 7, the quality of the
article was considered high; when the ﬁnal score was 6 or
7, the quality of the article was consideredmedium;when
the ﬁnal score was less than 6, the quality of the article
was considered low.
Data analysis
Before merging raw data into the software, the likelihood
ratio (I2) index and Cochran Q test were used to quantify
the heterogeneity of the enrolled articles. The percentage
measure of the heterogeneity among the enrolled articles
was calculated as I2 index.When I2 was greater than 25%,
the randomeffectsmodelwas used to summarize the result
of sensitivity; when I2 was less than 25%, which meant
little heterogeneity in the enrolled articles, the ﬁxed effects
modelwas used for data analysis.Whenusing theCochran
Q test for likelihood ratio, if the P value was less than .05,
the articles were deemed heterogeneous. Threshold effect
was estimated byusing theMeta-Disc software to evaluate
the possible factors causing the heterogeneity in
combining individual statistical data. The correlation
Table I. Summary of patient characteristics
References Country (publish year) Patient number Study design Male:Female Mean age (years)
Measurement
(US ¼ 1, CT ¼ 2, MRI ¼ 3)
Eida et al.14 Japan (2007) 31 Unknown 1:1.4 63 3
Motoori et al.15 Japan (2005) 33 Unknown 1:0.3 60.8 3
Kurabayashi et al.16 Japan (2002) 30 Unknown 1:1.1 43.1 3
Takashima et al.17 Japan (2001) 72 Prospective 1:1.1 53 3
Takashima et al.18 Japan (1997) 53 Prospective 1:1.1 53 3
Inohara et al.19 Japan (2008) 81 Unknown Unknown Unknown 3
Arbab et al.20 Japan (2000) 22 Retrospective 1:1.4 Unknown 2, 3
Klintworth et al.21 Germany (2012) 57 Retrospective 1:1.1 53.3 1
Wu et al.22 China (2012) 189 Retrospective 1:1.1 42.3 1
Jin et al.23 China (2011) 51 Unknown 1:0.8 44 2
Lechner Goyault et al.24 France (2011) 60 Retrospective 1:0.9 59.4 3
Paris et al.25 France (2005) 86 Retrospective Unknown Unknown 3
Takashima et al.26 Japan (1999) 26 Unknown 1:0.5 56 3
Corr et al.27 Hong Kong (1993) 40 Prospective Unknown Unknown 1
Kim et al.28 South Korea (1998) 147 Retrospective Unknown Unknown 2, 3
Yabuuchi et al.29 Japan (2003) 42 Prospective Unknown Unknown 3
Gritzmann et al.30 Austria (1989) 289 Retrospective Unknown Unknown 1
Bryan et al.31 America (1982) 27 Retrospective Unknown Unknown 2
Park et al.32 Korea (2012) 67 Retrospective 1:0.4 61.1 2
US, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging.
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were also calculated. When there was a positive correla-
tion, which indicated a threshold effect, summary
receiver-operating characteristic curve (SROC) and area
under curve (AUC) were calculated. When there was a
negative correlation, subgroup analysis was performed.
Spearman correlation coefﬁcient and P value were
calculated for symmetry of SROC. When P was greater
than .05, the Mantel-Haenszel model as well as both the
DerSimonia-Laird and Moses-Shapiro-Littenber models
were used to calculate diagnostic odds ratio (DOR) and
SROC; when P was less than .05, the Moses-Shapiro-
Littenber model was used.14
Sensitivity was calculated as TP/(FNþTP), speciﬁcity
was calculated as TN/(FPþTN), and 95% conﬁdence
interval (CI) was also estimated; when calculating
sensitivity and speciﬁcity for each article, all lesionswere
included. SROC was used to evaluate the overall diag-
nosis performance of determined groups. AUC was
compared by using the Mann-Whitney U test. Q value
was used to represent a global measure of test accuracy.15
TheDORofUS,CT, andMRIwas calculated to illustrate
positive likelihood ratio over negative likelihood. Meta-
regression was used to test the potential source of het-
erogeneity, which was considered signiﬁcant when the P
value was less than .1. Publication bias was presented
using a funnel plot, and Egger regression test was used to
examine the asymmetry of the funnel.
Statistical analysis was performed with STATA sta-
tistical software (Version 11.0, StataCorp LP, College
Station, TX) and Meta-Disc software (Version 1.4,
Madrid, Spain). When the P value was less than .05, the
difference was considered statistically signiﬁcant.RESULTS
Literature evaluation
One hundred and two articles were identiﬁed in the liter-
ature databases, and 73articleswere excluded after reading
their abstracts. According to the inclusion and exclusion
criteria, 10 articles were excluded, and only 19 articles
could be used for analysis,16-32 as described in detail in
Figure 1. With the QUADAS tool, 8 articles were evalu-
ated as high-quality articles, 10 articles were deemed me-
dium quality, and only 1 article was of low quality. There
were 784 patients with 792 SGTs enrolled in this analysis.
The male-to-female ratio was 1:1.05. The patients’ ages
ranged from 42 to 63 years, with a mean of 52.4  7.9
years. There were 12 articles evaluating MRI, 5 articles
evaluating CT, and 4 articles evaluating US (Table I).
Publication bias and heterogeneity
Because there were only 5 and 4 articles evaluating CT
and US, respectively, the sample size was too small for
statistical analysis when the funnel plot was used to test
diagnostic effect; 12 articles evaluating MRI were used
to test diagnostic effect using the funnel plot. Infor-
mation from each patient was incorporated into the
funnel plot, the x-axis was the DOR and the y-axis was
the inverse of the effective sample size (1/ESS).
Consequently, a regression line and a signiﬁcant
regression coefﬁcient (13.39; 95% CI ¼ 47.62-
20.83; P ¼ .393) could be obtained, and the funnel plot
was symmetric (Supplementary Figure S2). Meta-
regression was used to analyze the relationship between
the DOR and the composite variables; unfortunately, no
signiﬁcant relationship was found (P > .05). The
Spearman correlation coefﬁcients for MRI, CT, and US
Fig. 2. Forest plot (random effects model) of pooled sensitivity and speciﬁcity for differential diagnosis between benign and
malignant salivary gland tumors with ultrasonography (A, B), computed tomography (C, D), and magnetic resonance imaging
(E, F), respectively.
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.200), respectively.
Diagnostic sensitivity and specificity of
ultrasonography
When US was used to differentiate malignant SGTs
from benign SGTs, for sensitivity calculation, the I2
index was 68.1%, and the Cochran Q test was 9.4(df ¼ 3; P ¼ .024); a random effects model was used,
with a pooled sensitivity of 63% (95% CI 52%-73%).
For speciﬁcity calculation, the I2 index was 31.1%,
and the Cochran Q test was 92.0 (df ¼ 3; P ¼ .225); a
ﬁxed effects model was used, with a pooled
speciﬁcity of 92% (95% CI 89%-94%) (Figure 2, A
and B).
Fig. 2. (continued).
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tomography
For calculation of the sensitivity of CT, the I2 index was
0, and the Cochran Q test was 2.1 (df ¼ 4; P ¼ .720); a
ﬁxed effects model was used, with a pooled sensitivity
of 83% (95% CI 74%-90%). For speciﬁcity calculation,
the I2 index was 80%, and the Cochran Q test was 20.4
(df ¼ 4; P < .001); a random effects model was used,
with a pooled speciﬁcity of 85% (95% CI 79%-90%)
(see Figure 2, C and D).
Diagnostic sensitivity and specificity of magnetic
resonance imaging
For calculation of the sensitivity of MRI, the I2 index
was 55.0%, and the Cochran Q test was 24.45 (df ¼ 11;
P ¼ .011); a random effects model was used, with a
pooled sensitivity of 81% (95% CI 73%-87%). For
speciﬁcity calculation, the I2 index was 82.9%, and the
Cochran Q test was 64.5 (df ¼ 11; P < .001); a random
effects model was used, with a pooled speciﬁcity of
89% (95% CI 85%-92%) (see Figure 2, E and F).Area under curve and diagnostic odds ratio
For US, the AUC under SROC was 0.934  0.058,
and the Q index was 0.870  0.072 (Figure 3, A). For
CT, the AUC under SROC was 0.912  0.889, and the
Q index was 0.844  0.025 (see Figure 3, B). For
MRI, the AUC under SROC was 0.903  0.045, and
the Q index was 0.834  0.049 (see Figure 3, C). The
pooled DORs for US, CT, and MRI were 16.46 (95%
CI 5.40-50.15; P ¼ .048), 28.81 (95% CI 13.58-61.12;
P ¼ .590), and 34.94 (95% CI 11.08-110.24; P <
.001), respectively. There was no signiﬁcant differ-
ence among these three groups (Supplementary
Figure S3).
According to the SROC analysis, there was no sig-
niﬁcant difference among these three groups. However,
there was statistical difference in sensitivity between
the US and CT modalities (P value ¼ .027, Kruskal-
Wallis test) and between the US and MRI modalities
(P value ¼ .045, Kruskal-Wallis test). The pooled
sensitivity of CT and MRI was higher than that of US
for clinical diagnosis of SGTs.
Fig. 3. Summary receiver-operating characteristic curve for
differential diagnosis of between benign and malignant sali-
vary gland tumors by ultrasonography (A), computed to-
mography (B), and magnetic resonance imaging (C). SROC,
summary receiver operating characteristic; AUC, area under
the curve; Q*, point at which sensitivity and speciﬁcity was
equal.
OOOO ORIGINAL ARTICLE
Volume 119, Number 2 Liu et al. 243DISCUSSION
In this study, we obtained the SROC for the diagnostic
accuracy of the US, CT, and MRI modalities in patients
with SGTs. AUC was considered the critical standard in
judging diagnostic performance, and there was no sta-
tistical difference of AUC among the US, CT, and MRImodalities. From a forest map of sensitivity and spec-
iﬁcity, there was high speciﬁcity but relatively poor
sensitivity in the US modality; however, the combina-
tion of speciﬁcity and sensitivity in the MRI modality
was the highest among the three modalities.
Imaging examination is very important for clinical
diagnosis in patients with SGTs when FNAB is difﬁcult
to perform because of unusual location or patients’
unwillingness to undergo FNAB. Early studies, in
which the diagnostic criteria remained mostly consis-
tent in each detection procedure, reported US to have
high sensitivity.17,18,27,30,33 With the new index applied
in the detection procedure, diagnostic results varied
greatly. For example, color Doppler ﬂow imaging is an
important tool in making a sufﬁciently deﬁnite diag-
nosis; however, the information on blood supply could
not predict signiﬁcant differences between benign and
malignant SGTs.34 Meanwhile, gray-scale sonographic
images are effective features to calculate the properties
of SGTs, and B-mode ultrasonography and sonoelas-
tography could improve the diagnostic perfor-
mance.21,35 The speciﬁcity of US is generally good
because the majority of SGTs are benign and only a
small amount of SGTs are malignant (9.5%).36 During
the diagnostic procedure with US in patients with
SGTs, some characteristics, such as lesion size, echo-
genicity, margin regularity, and vascularity, should be
taken into consideration; furthermore, clinical data,
such as medical history, speed of growth, pain, and
facial palsy, should also be considered. For some cases,
such as a large mass in a deep lobe of the salivary
gland, differential diagnosis is difﬁcult with US. In such
situations, other imaging examinations, such as CT and
MRI, might be helpful.
CT and MRI are commonly used as imaging diag-
nostic methods.16,17,23,27,37 Unfortunately, neither of
them has been shown to reach the ideal AUC achieved
by US. The advantages of CT and MRI are signiﬁcant,
and they continue to play an important role in the
management of patients with SGTs. CT, with its good
anatomic resolution, soft tissue contrast, and detailed
morphology, can provide meaningful information to
surgeons during the procedure.23,28,31 MRI, with its
good spatial and contrast resolution and avoidance of
radiation exposure and interfering factors, such as im-
aging parameters and iron accumulation, could also
provide useful information.16,17 The disadvantages of
CT and MRI include time and monetary costs; for pa-
tients with an allergenic constitution and kidney
dysfunction, use of the contrast agent is inappropriate.38
Furthermore, some parents are uncomfortable about the
radiation exposure to their children during CT
scanning.
There are some limitations in this study when
selecting studies, because a few studies come from
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different clinical researches; radiologists from different
hospitals may have different opinions on diagnosing
periods. So, further clinical studies are encouraged to
give more powerful results by improving inclusion and
diagnostic criteria.
Although there is no signiﬁcant difference with re-
gard to diagnostic accuracy between benign and ma-
lignant SGTs in the present study, it is recommended
that CT or MRI could be used as a recommended ex-
amination method in patients with SGTs with clinical
symptoms, such as pain, rapid growth, and facial pa-
ralysis. Since CT and MRI have good sensitivity, they
provide useful anatomic information to surgeons and
for nonsurgical treatment planning.15,21
CONCLUSIONS
US, CT, and MRI are reliable methods in diagnosing
SGTs clinically. There is no statistical difference between
CT and MRI; however, MRI is more expensive than CT.
CT is recommended as an effective imaging tool in pa-
tients with primary SGTs; MRI is also recommended for
its highest sensitivity and speciﬁcity for differential diag-
nosis between benign and malignant SGTs.
We thank Dr. Jian-feng Luo for providing statistical support
and editing the manuscript.
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Supplementary Fig. S1. Chart showing the study design characteristics based on the QUADAS tool.
Supplementary Fig. S2. The Deek funnel plot for testing
publication bias.
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Supplementary Fig. S3. The Forest plot (random effects model) of pooled diagnostic odds ratio for differential diagnosis of be-
tween benign and malignant salivary gland tumors by ultrasonography (A), computed tomography (B), and magnetic resonance
imaging (C).
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